Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use
申请人:Robinson Clive
公开号:US20120322722A1
公开(公告)日:2012-12-20
The present invention pertains generally to the field of therapeutic compounds and more specifically to certain pyruvamide compounds of the formula (X) (for convenience, collectively referred to herein as “PVA compounds”), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.
本发明一般涉及治疗化合物领域,更具体地涉及某些丙酮酰胺化合物的公式(X)(为方便起见,以下统称为“PVA化合物”),该化合物在某些情况下抑制尘螨1组蛋白酶过敏原(例如Der p 1、Der f 1、Eur m 1)。本发明还涉及包含这种化合物的药物组合物,以及在体外和体内使用这种化合物和组合物来抑制尘螨1组蛋白酶过敏原,并用于治疗由尘螨1组蛋白酶过敏原介导的疾病和疾病,通过抑制尘螨1组蛋白酶过敏原而得到缓解的疾病和疾病;哮喘;鼻炎;过敏性结膜炎;特应性皮炎;由尘螨引发的过敏症状;由尘螨1组蛋白酶过敏原引发的过敏症状;以及犬类特应性。